ACUTE LYMPHOCYTIC LEUKEMIA
Clinical trials for ACUTE LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
BESPONSA safety tracked in over 400 leukemia patients
Disease control CompletedThis study looked at the safety of the drug BESPONSA in 421 people with a type of blood cancer called acute lymphocytic leukemia that had come back or stopped responding to treatment. All participants received BESPONSA as prescribed by their doctor. Researchers tracked side effec…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC